CapLaw-2021-56

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, on 27 July 2021 announced that it is acquiring Affiris SA’s portfolio of therapeutics targeting alpha-synuclein (a-syn) as well as cash for 7.1 million shares based on a price of USD 8.26 per common share of AC Immune. The acquisition…